Global Alliance for TB Drug Development

The AMR Accelerator, a public-private partnership, aims to accelerate antibiotic development and build research capabilities for treating resistant infections. It has progressed 44 antibacterial programmes, developed research infrastructures, and fostered cross-project networks. Challenges include collaboration complexities, ensuring synergies, and sustainability of assets post-project. The initiative calls for long-term funding to sustain expertise and attract new talent to the field.